Anshu Goyal has supported the early research and development in Hormonal Dysregulation for over a decade before launching Xyone Therapeutics with Dr Ravi Jasuja and Dr Kharbanda. He had a long wall street career as a successful investor and has led investment teams at major hedge funds including Millennium and Exodus Partners for many years. When away from work, he is an avid hiker, backpacker and skier.
Dr. Jasuja serves as the Chief Scientific Officer of the XYone Therapeutics and is an
expert in the use of biophysical techniques for investigating the interactions of steroid hormones with their cognate receptors and binding proteins. He led innovative research that uncovered the mechanistic origin of errors in the current model of testosterone binding to SHBG and provided the insight that led to the generation of the new TruT™ method for determining free testosterone concentration. He is a faculty member at Harvard Medical School at the Brigham and Women’s Hospital and Director Translation Research & Discovery at the Boston Claude D Pepper Center.
Dr. Kharbanda received his Ph. D in cell biology in 1986 from the All India Institute of Medical Sciences, New Delhi. He joined the Dana-Farber Cancer Institute, Harvard Medical School in 1986 as a Research Fellow and undertook extensive research work in the area of oncology drug discovery and development. In 1991, he was promoted to Assistant Professor at Harvard Medical School where he worked as a faculty member for 15 years. Dr. Kharbanda is a co-author on more than 200 papers published in peer-reviewed scientific journals and holds > 40 patents and patent applications in the area of oncology drug discovery. In 2000, he joined Ilex Oncology Inc., an oncology-driven pharmaceutical company, as Vice-President (head of R&D), where his responsibilities included development of novel drugs for cancer. Dr. Kharbanda was a member of the team which successfully developed two oncology drugs that are approved by US-FDA. Following the acquisition of Ilex Oncology by Genzyme Corporation, Dr. Kharbanda founded companies that include Genus Oncology (acquired by XYone), Linus Oncology (acquired by Gibson Oncology) and NanoProteagen (acquired by Hillstream Biopharma, a NASDAQ listed company). Dr. Kharbanda is currently working at XYone as the Chief Operating Officer and his focused goal is to develop novel therapeutic approaches for the treatment of diverse types of carcinomas.
Dr. Bhasin is an internationally recognized expert in human aging, clinical trials of function promoting therapies for older adults, functional decline in aging, and testosterone biology. He chaired the Endocrine Society’s Expert Panel for the development of Guidelines for Testosterone Therapy. He is a translational researcher, with over 250 peer-reviewed manuscripts, 130 reviews and book chapters. Dr. Bhasin’s research has led to new applications of androgens and selective androgen receptor modulators. His pioneering research in androgen biology and anabolic therapies for aging-associated sarcopenia has been supported by several NIH-funded grants.. He is a Professor of Medicine, Harvard Medical School and Principal Investigator & Director at the Boston Claude D Pepper Center and Director of Research Program in Men’s health: aging & Metabolism, at Brigham & Women’s Hospital. He received his MD from the All India Institute of Medical Sciences in New Delhi, India, residency training at Northwestern University Medical School and fellowship training in Endocrinology and Nutrition at Harbor-UCLA Medical Center in Los Angeles, CA.
Dr. Panchamoorthy received his Ph. D in Biochemistry and Immunology in 1988 from the All India Institute of Medical Sciences, New Delhi. In 1989, he joined the Dana-Farber Cancer Institute as a Research Fellow where he gained expertise in T cell receptor, followed by his training in diverse immunological signaling mechanisms at the Brigham and Women’s Hospital - Harvard Medical School. He joined AstraZeneca Pharmaceuticals in 1997 and led a team of scientists in the Target Discovery Group for cancer and inflammation. In 2003, he moved to Sanofi Pasteur as a Manager and was responsible for the validation of licensed vaccine products. He joined Genus Oncology in 2008 and developed the immuno-oncology programs. His goal is to develop novel antibody based therapeutic approaches for diverse types of solid tumors.
Brian is a computational scientist, driving the development of methods, numerical techniques, data management, and software behind TruT™. Brian comes with research and professional experience in diverse array of applications including life sciences, physics, and engineering. Specializations include numerical modeling, bioinformatics, and data science. He was worked as a data science, scientific computing, and software consultant in academic partnerships and in industry with both small biotechs and large pharmaceutical companies. Brian completed a B.S. in mechanical engineering and mathematics and holds a Ph.D. in theoretical and applied mechanics from Cornell University.
Dylan has served as Director of Business Development for a pharmaceutical company and its operational reagents business. He has over 20 years of experience with fluorescence-based platforms, reagents, and applications and has worked on commercialization of both research-use-only and diagnostic instruments. He has directed development teams and worked with product management and marketing teams to successfully deploy unique products for both small start-ups as well as large, global biotechnology companies. His experience includes OEM and direct sales, strategic product management, and direction of R&D efforts to support company objectives. Dylan completed a B.S. in Biology and a Ph.D. in Biochemistry and Biophysics from Oregon State University and is currently pursuing an M.B.A. at the University of Massachusetts, Amherst. He has served as PI, co-PI, or Key Personnel, on Phase I, II and III programs funded by NIH and the Department of Homeland Security.
Sam is a business lawyer, serving as general counsel and advisor to businesses in the pharmaceutical, biotech and specialty pharmaceutical, medical device and software industries. His clients are focused on rapid growth through highly incentivized and educated workforces and focused business plans. He generally counsels clients developing valuable proprietary assets and a strong brand name, with an emphasis on near- to medium-term exit strategy, or an acquisitive/accretive strategy for growth. Sam works with public companies in sophisticated transactional matters, prominent universities and hospitals in commercializing intellectual property, newly formed corporations in a general counsel capacity, and private equity and venture investors worldwide.
Sam has extensive experience with venture capital financings, licensing and partnership agreements, mergers and acquisitions, and joint ventures. He frequently works with companies doing business in India, China, Canada and many other jurisdictions worldwide.
XYone Therapeutics Inc
780 Dedham Road,
Suite 800 Canton